China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours

Phase 1AK158D1Positive

AI Analysis

Akeso received clearance from China's NMPA to initiate a Phase I clinical trial of AK158D1 in patients with advanced malignant solid tumours.

Phase

Phase 1

NMPA/CDE clearance to begin Phase I trial

Importance:5/10

Sentiment:

0.70

regulatory approvalNMPAChinaoncologysolid tumorstrial initiation

Related Companies

Read the original article

Published by Clinical Trials Arena on September 18, 2026 8:34 AM